Sharing of real cases of Midostaurin’s therapeutic effects

In acute myeloid leukemia(AML)especially in FLT3 mutation-positive people, traditional chemotherapy often has limited efficacy and high relapse rate. The emergence of Midostaurin provides new hope for these patients. As an oral multi-target tyrosine kinase inhibitor, midostaurin can block FLT3 and other signaling pathways related to tumor proliferation, and has shown significant benefits in real overseas application cases.

For example, an overseas patient received standard chemotherapy combined with midostaurin when he was first diagnosed with FLT3-mutated AML. After a complete course of treatment, the leukemia cells in the bone marrow dropped significantly and the disease entered complete remission. The significance of this case is that midostaurin does not simply replace chemotherapy, but has a synergistic effect with chemotherapy, allowing patients to obtain better curative effects at an early stage and creating conditions for subsequent hematopoietic stem cell transplantation. For patients who were previously unable to successfully bridge to transplantation, midostaurin undoubtedly improves the chances of long-term survival.

In the case of systemic mastocytosis, patients often develop multisystem symptoms due to organ involvement, such as hepatosplenomegaly, bone pain, and even gastrointestinal dysfunction. After some patients received midostaurin treatment, their serum trypsin levels decreased, the burden on their organs was reduced, and their symptoms improved significantly. Although such cases are rare, they have provided clinicians with more treatment ideas in the real world.

In addition, some patients received midostaurin monotherapy due to multiple relapses of AML. After a few weeks of use, hematological indicators gradually improved, white blood cell counts tended to be normal, clinical symptoms were relieved, and quality of life was improved. Such cases demonstrate the potential value of midostaurin in relapsed and refractory patients. Although the drug does not guarantee that all patients will achieve ideal results, in the context of precision medicine and through genetic testing to select suitable people, the number of people who can benefit from midostaurin is constantly expanding.

Reference materials:https://go.drugbank.com/drugs/DB06595